Abstract
The bradykinin B2 receptor antagonist icatibant is effective in angiotensin-converting enzyme inhibitor-induced angioedema. The drug is not approved officially for this indication and has to be administered in an emergency situation off-label. Corticosteroids or antihistamines do not seem to work in this condition. The effectiveness of C1-esterase-inhibitor in angiotensin-converting enzyme-induced angioedema must be verified in a double-blind study.
Keywords:
ACE inhibitor; Angioedema; Bradykinin; Bradykinin receptors.
Copyright © 2016 Elsevier Inc. All rights reserved.
MeSH terms
-
Angioedema / diagnosis*
-
Angioedema / drug therapy
-
Bradykinin / analogs & derivatives
-
Bradykinin / therapeutic use
-
Bradykinin B2 Receptor Antagonists / therapeutic use
-
Diagnosis, Differential
-
Drug-Related Side Effects and Adverse Reactions / diagnosis*
-
Drug-Related Side Effects and Adverse Reactions / drug therapy
-
Emergency Medical Services
-
Epiglottis / immunology
-
Epiglottis / pathology*
-
Humans
-
Off-Label Use
-
Renin / adverse effects
-
Tongue / immunology
-
Tongue / pathology*
-
Urticaria / diagnosis*
Substances
-
Bradykinin B2 Receptor Antagonists
-
icatibant
-
Renin
-
Bradykinin